PEROL M.
- Country
- France
- Department
- Oncology medical
Research Overview
- Tarlatamab plus Durvalumab versus Durvalumab Alone in Patients with Extensive-Stage Small Cell Lung Cancer Following Platinum-Etoposide Therapy
- Pumitamig Versus Durvalumab After Concurrent Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer Without Progression
- Phase III Randomized Study of Osimertinib with or without Platinum-Based Chemotherapy in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 73 of 220 partner sites.
Specializations
Non-Small Cell Lung Cancer (NSCLC)
The investigator specializes in studying advanced treatment approaches for non-small cell lung cancer, with particular emphasis on cases involving specific genetic mutations including EGFR, HER2, and ROS1 alterations.
- Early-stage resectable NSCLC
- Metastatic NSCLC treatment
- Targeted therapy resistance
Their work encompasses both early-stage and advanced disease states, focusing on novel therapeutic combinations and targeted approaches.
Small Cell Lung Cancer
The investigator conducts research in small cell lung cancer treatment, particularly focusing on extensive-stage SCLC and novel therapeutic combinations.
- Limited-stage SCLC
- Extensive-stage disease management
- Immunotherapy applications
Their research includes evaluation of innovative treatment strategies for both newly diagnosed and previously treated SCLC patients.
Precision Medicine Approaches
The investigator explores personalized treatment strategies based on specific molecular markers and genetic mutations in lung cancer.
- Biomarker-driven therapy
- Targeted therapeutic agents
- Combination treatment strategies
Their work integrates molecular testing and targeted therapies to develop more effective personalized treatment approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.